Correlation of Radiation Dose and PSA Blood Level in the Radiotherapy of Prostate Cancer:  A retrospective case series

Ade Margaretha LT; Soehartati A. Gondhowiardjo

doi:10.32532/jori.v11i2.110

Correlation of Radiation Dose and PSA Blood Level in the Radiotherapy of Prostate Cancer: A retrospective case series

Ade Margaretha LT, Soehartati A. Gondhowiardjo

Sari

Background: The objective of this study was to analyze the correlation of radiation dose and Prostate-Specific Antigen (PSA) blood level following radiation therapy in prostate cancer.

Methods: The study population was serial of 13 patients with histologically proven T1b-T4, any N, M0 prostate adenocarcinoma, having any Gleason score with any PSA before and after complete EBRT (external beam radiotherapy), from January 2009 to December 2010 and evaluated for PSA decrease post-EBRT.

Results: Out of 13 patients, one patient received 62 Gy, one patient received 72 Gy, and 11 patients received 80 Gy. PSA blood level was decreased (median 5.4, 9.43 and 25.27, respectively) in all patients.

Conclusion: This case series results were consistent with the results of previous studies that a higher radiation dose will have a higher PSA decrease with a tolerable side effect.

Kata Kunci

Radiasi; prostat; adenokarsinoma

Teks Lengkap:

PDF (English)

Referensi

International Agency for Research on Cancer. Estimated number of prevalent cases (5-year) Asia, Indonesia, males, all ages [Internet]. 2019. Available from: https://gco.iarc.fr/today/online-analysis-multi-bars

Ninke WH. Estimated number of prevalent cases (5-year) worldwide, males, all ages [Internet]. 2019. Available from: https://gco.iarc.fr/today/online-analysis-multi-bars

Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer Supplementary Appendix. N Engl J Med [Internet]. 2016;375(15):1415–24. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1606220

Halperin, Edward C, David E.Wazer CAP. Principles and Practice of Radiation Oncology. 7th ed. 2019. 14–15 p.

Salembier C, Villeirs G, Bari B De, Hoskin P, Pieters BR, Vulpen M Van, et al. ESTRO ACROP guideline ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer. Radiother Oncol [Internet]. 2018;127(1):49–61. Available from: https://doi.org/10.1016/j.radonc.2018.01.014

Beckendorf V, Guerif S, Le Prisé E, Cosset JM, Bougnoux A, Chauvet B, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys. 2011;80(4):1056–63.

Kuban DA, Levy LB, Cheung MR, Lee AK, Choi S, Frank S, et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys. 2011;79(5):1310–7.

Dearnaley DP, Jovic G, Syndikus I, Khoo V, Cowan RA, Graham JD, et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: Long-term results from the MRC RT01 randomized controlled trial. Lancet Oncol [Internet]. 2014;15(4):464–73. Available from: http://dx.doi.org/10.1016/S1470-2045(14)70040-3

Peeters STH, Heemsbergen WD, Koper PCM, Van Putten WLJ, Slot A, Dielwart MFH, et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24(13):1990–6.

Viani GA, Stefano EJ, Afonso SL. Higher-Than-Conventional Radiation Doses in Localized Prostate Cancer Treatment: A Meta-analysis of Randomized, Controlled Trials. Int J Radiat Oncol Biol Phys. 2009;74(5):1405–18.

Hou Z, Li G, Bai S. High dose versus conventional dose in external beam radiotherapy of prostate cancer: a meta-analysis of long-term follow-up. J Cancer Res Clin Oncol. 2015;141(6):1063–71.

Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from Proton Radiation Oncology Group/American College Of Radiology 95-09. J Clin Oncol. 2010;28(7):1106–11.

Kalbasi A, Li J, Berman AT, Swisher-McClure S, Smaldone M, Uzzo RG, et al. Dose-escalated irradiation and overall survival in men with nonmetastatic prostate cancer. JAMA Oncol. 2015;1(7):897–906.

DOI: https://doi.org/10.32532/jori.v11i2.110 <